Isaac R Francis
Overview
Explore the profile of Isaac R Francis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
2350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Konstantinoff K, Morani A, Hope T, Bhosale P, Francis I, Yano M, et al.
Abdom Radiol (NY)
. 2023 Feb;
48(5):1843-1853.
PMID: 36737523
The clinical and imaging presentation of pancreatic neuroendocrine tumors (PanNETs) is variable and depends on tumor grade, stage, and functional status. This degree of variability combined with a multitude of...
2.
Barrs C, Itani M, Zulfiqar M, Mhlanga J, Francis I, Morani A, et al.
Abdom Radiol (NY)
. 2022 Oct;
47(12):3986-3992.
PMID: 36201054
Purpose: Standardized reporting in radiology has an established role in numerous disease processes, with added benefits in oncology of reduced variability, and generation of a thorough and pertinent report with...
3.
Sharbidre K, Morani A, Zahid M, Bhosale P, Lall C, Francis I, et al.
Abdom Radiol (NY)
. 2022 Apr;
47(12):4042-4057.
PMID: 35412112
Male genitourinary neuroendocrine neoplasms (GU-NENs) are rare, without any definite imaging characteristics. The WHO classified neuroendocrine neoplasms in the 2016 classification of the tumors of the urinary tract and genital...
4.
Roseland M, Francis I, Shampain K, Stein E, Wasnik A, Millet J
Abdom Radiol (NY)
. 2022 Apr;
47(12):3993-4004.
PMID: 35411433
Gastric neuroendocrine neoplasms are uncommon tumors with variable differentiation and malignant potential. Three main subtypes are recognized: type 1, related to autoimmune atrophic gastritis; type 2, associated with Zollinger-Ellison and...
5.
Sun D, Hadjiiski L, Alva A, Zakharia Y, Joshi M, Chan H, et al.
Tomography
. 2022 Mar;
8(2):644-656.
PMID: 35314631
This observer study investigates the effect of computerized artificial intelligence (AI)-based decision support system (CDSS-T) on physicians' diagnostic accuracy in assessing bladder cancer treatment response. The performance of 17 observers...
6.
Galgano S, Morani A, Gopireddy D, Sharbidre K, Bates D, Goenka A, et al.
Abdom Radiol (NY)
. 2022 Mar;
47(12):3962-3970.
PMID: 35244755
Pancreatic neuroendocrine neoplasms (PaNENs) are a unique group of pancreatic neoplasms with a wide range of clinical presentations and behaviors. Given their heterogeneous appearance and increasing detection on cross-sectional imaging,...
7.
Hecht E, Khatri G, Morgan D, Kang S, Bhosale P, Francis I, et al.
Abdom Radiol (NY)
. 2020 Nov;
46(4):1586-1606.
PMID: 33185741
There have been many publications detailing imaging features of malignant transformation of intraductal papillary mucinous neoplasms (IPMN), management and recommendations for imaging follow-up of diagnosed or presumed IPMN. However, there...
8.
Hadjiiski L, Cha K, Cohan R, Chan H, Caoili E, Davenport M, et al.
Tomography
. 2020 Jun;
6(2):194-202.
PMID: 32548296
We evaluated the intraobserver variability of physicians aided by a computerized decision-support system for treatment response assessment (CDSS-T) to identify patients who show complete response to neoadjuvant chemotherapy for bladder...
9.
Liles A, Francis I, Kalia V, Kim J, Davenport M
AJR Am J Roentgenol
. 2019 Dec;
214(3):487-492.
PMID: 31887096
The purposes of this study were to investigate factors driving callback MRI and CT examinations and to discern opportunities for optimizing the patient experience by reducing future callbacks. All consecutive...
10.
Hersberger K, Mendiratta-Lala M, Fischer R, Kaza R, Francis I, Olszewski M, et al.
J Natl Compr Canc Netw
. 2019 Dec;
17(12):1505-1511.
PMID: 31805530
Background: Objective radiographic assessment is crucial for accurately evaluating therapeutic efficacy and patient outcomes in oncology clinical trials. Imaging assessment workflow can be complex; can vary with institution; may burden...